Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).
Marlies van DijkKris J M MoorenJan-Willem K van den BergWendy J C van Beurden-MoeskopsRoxane Heller-BaanSander M de HossonWai Yee Lam-WongLiesbeth PetersKarin PoolHuib A M KerstjensPublished in: BMC pulmonary medicine (2021)
Evidence for opioids for refractory dyspnea in COPD is not as robust as usually appreciated. We designed a study comparing both the more commonly used opioid morphine, and transdermal fentanyl to placebo. The cross-over design will help to get a better impression of patient preferences. We believe our study design to investigate both sustained-release morphine and transdermal fentanyl for refractory dyspnea will provide valuable information for better treatment of refractory dyspnea in COPD. Trial registration NCT03834363 (ClinicalTrials.gov), registred at 7 Feb 2019, https://clinicaltrials.gov/ct2/show/NCT03834363 .
Keyphrases
- chronic obstructive pulmonary disease
- double blind
- chronic pain
- pain management
- lung function
- phase iii
- case report
- clinical trial
- study protocol
- advanced cancer
- placebo controlled
- computed tomography
- phase ii
- healthcare
- palliative care
- cross sectional
- randomized controlled trial
- magnetic resonance
- positron emission tomography
- smoking cessation
- air pollution
- image quality
- health information